Abridge
The best-evidenced ambient scribe in healthcare and the most closed: deep Epic context and line-by-line source traceability, zero developer surface, and a peer-reviewed benefit of 16 minutes a day.
PRICING
| Enterprise licence | ~$208/mo | per clinician, third-party estimate from contract analysis; Abridge publishes no price |
| Full implementation | $250-$500/mo | per provider, depending on integration depth and contract terms (third-party estimate) |
| Individual / small practice | Not sold | no self-serve signup, no free trial for individual clinicians |
Every figure here is third-party estimate, not vendor-published. Abridge sells through negotiated health-system contracts only. Treat the numbers as a range to open a procurement conversation with, not a quote.
checked 2026-08-07 · vendor pricing page
Element scores
Strengths
Two things make Abridge hard to argue with. The Contextual Reasoning Engine assembles context most competitors never touch: prior encounters, ED documentation, nursing assessments, labs, imaging and health-system-specific guidelines, all feeding one note. And Linked Evidence ties every generated line back to the exact audio segment that produced it, which turns 'do I trust this note' from a leap of faith into a click. The evidence base is real too. The April 2026 JAMA multisite study (8,581 clinicians across five US academic centres, Abridge among three vendors studied) measured 13.4 fewer minutes of EHR time and 16.0 fewer minutes of documentation time per 8 scheduled patient hours. Best in KLAS for ambient AI in both 2025 and 2026. 300+ health systems, 100M+ conversations a year, 28+ languages, 50+ specialties.
Honest dings
The platform is closed. No public developer API, no SDK, no MCP, no A2A; third-party integration runs through Epic's Partners and Pals programme rather than through Abridge. That is why the periodic-table score lands mid-band despite a category-leading product: the interoperability, evaluation and model-choice columns are simply not offered. Two more things to price in. First, the safety burden stays with the clinician: Biro et al. found errors in 70% of draft notes across two commercial ambient products, and Ontario's auditor general documented hallucinated drug data and missing mental-health detail in provincial testing in May 2026, so no ambient vendor gets a free pass here. Second, the benefit is real but modest and unevenly distributed. The JAMA study found no significant change in after-hours EHR work, revenue gain of about $167 per clinician per month, and only 32% of adopters used the tool in at least half their visits, which is exactly the group that got double the time saving. Pricing is unpublished, enterprise-only and US-only in practice; UK and EU adoption is limited.
Sources
Every audit lists the research it rests on — transparency and traceability are the product. Tools evolve: each audit is a snapshot of its audit date, and re-audits supersede older versions (kept below for reference).
- abridge.com/press-release/patient-centered-clinicia… — Official keynote release 11/06/2026: 300+ health systems, 100M+ conversations annually, 250M+ patients, NVIDIA Nemotron foundation model on Blackwell, Northwestern Medicine enterprise rollout, pre-visit/in-visit/post-visit platform scope (accessed 2026-08-07)
- abridge.com/abridge-contextual-reasoning-engine — Official: Contextual Reasoning Engine surfaces — EHR context, predicted problems, orders, coding, Linked Evidence tying outputs to source data (accessed 2026-08-07)
- pubmed.ncbi.nlm.nih.gov/41920565 — Primary independent evidence. Rotenstein et al., 'Changes in Clinician Time Expenditure and Visit Quantity With Adoption of AI-Powered Scribes: A Multisite Study', JAMA 01/04/2026, doi:10.1001/jama.2026.2253 — 8,581 clinicians, 1,809 adopters, five US academic centres, vendors incl. Abridge; -13.4 min EHR time, -16.0 min documentation time, +0.49 visits/week, no significant change outside work hours (accessed 2026-08-07)
- massgeneralbrigham.org/en/about/newsroom/press-rele… — Independent corroboration of the JAMA study from a co-leading institution: only 32% of users adopted in ≥50% of visits; revenue effect $167/clinician/month; heavy users saw 2x EHR and 3x documentation time reduction (accessed 2026-08-07)
- pmc.ncbi.nlm.nih.gov/articles/PMC12973079 — Independent narrative review of ambient AI scribes: Biro et al. found 127 errors across 44 simulated encounters, with at least one error in 70% of draft notes (majority omissions); Kernberg et al. found 23.6 errors per case in a GPT-4 SOAP-note simulation (accessed 2026-08-07)
- mobihealthnews.com/news/abridge-partners-nvidia-exp… — Independent (HIMSS Media) 12/06/2026: 28+ languages, 50+ specialties, Nemotron on Blackwell, pre/mid/post-training on de-identified data (accessed 2026-08-07)
- fiercehealthcare.com/ai-and-machine-learning/nvidia… — Independent confirmation of the NVIDIA collaboration and that NVIDIA is also an investor via NVentures (accessed 2026-08-07)
- apis.io/providers/abridge — Third-party API directory: Abridge publishes no public self-service developer API; third-party integration runs through Epic's Partners and Pals programme (accessed 2026-08-07)
- trust.abridge.com — Official trust centre: SOC 2 Type 2 report available on request, AI training data/bias and AI monitoring controls listed (accessed 2026-08-07)
- support.abridge.com/hc/en-us/articles/3023529420161… — Official: all data stored and processed in HIPAA-secure US-based data centres (accessed 2026-08-07)
- deepcura.com/resources/abridge-ai-review — Competitor-published review (treat pricing as estimate, not vendor figure): ~$208/clinician/month, $250-500/provider full implementation, no self-serve signup, Epic-deep plus 5 other EHRs, no AI receptionist/fax/payment collection (accessed 2026-08-07)
- medcitynews.com/2026/06/abridge-clinical-ai — Independent: $830M raised since founding in 2018; 300+ health systems expected live on the new platform within 12 months (accessed 2026-08-07)
- medaidirectory.com/blog/ai-scribe-accuracy-hallucin… — Independent summary of the May 2026 Ontario auditor general findings: inadequate evaluation, hallucinations in testing and live use, fabricated information, incorrect drug data, missing mental health details (accessed 2026-08-07)
- iatrox.com/academy/toolkits/ai-scribe-comparison-20… — Independent clinician-authored comparison: Abridge is US-focused with limited UK adoption; Nabla and Heidi are the European-presence alternatives (accessed 2026-08-07)